Previous 10 | Next 10 |
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on July 28, 2020, at 12:00 p.m. EDT it will host a key opinion leader webinar on ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with c...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 5, 2020, at 4:30 p.m. EDT to discuss its financial results for the fiscal third quarter ended June 30, 2020. Conference Call and Webcast Details Investors may acce...
Shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) rose 34% last month, according to data provided by S&P Global Market Intelligence . That far outpaced the less than 2% gains of the S&P 500 and the NASDAQ Biotechnology Index . There wasn't any company-specific news to dri...
( Pexels ) Of all the investable sectors and industries, one of the top-performing over the past few months is biotechnology. Since its March low (18 th ), the SPDR Biotech ETF ( XBI ) has risen about 75% as investors speculate on virus treatment and vaccine rumors. Understandably, many in...
Arrowhead Pharmaceuticals ( ARWR ) is a small-cap biopharma that is developing a line therapies utilizing RNA interference ( RNAI ) to silence disease-causing genes. While the company has yet to get a product to market, Arrowhead has 2 partnerships with big pharma companies which lends some cr...
Introduction I have a portfolio of stocks, closed-end funds (BDCs - Business Development Companies) and short-term bond and money market funds. My portfolio's stock holdings are of a hybrid nature or quality; some are growth names, and some DGI (Dividend Growth Investing) stocks. The BDCs ...
Arrowhead Pharmaceuticals, Inc. ( ARWR ) is still waiting for a rebound back to former levels even though it has no significant overhangs to worry investors. Here's a look at Arrowhead's performance over 2020 compared to the SPDR S&P 500 Trust ETF ( SPY ) and the iShares Nasdaq Biotechnolo...
It is no secret that in the field of biotech, small- to mid-cap companies that develop innovative therapies for difficult-to-treat diseases (such as cancer) and a variety of rare conditions are often acquired by large-cap players for billions of dollars. Last year, the biggest ever biotech deal...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Virtual Healthcare Conference – June 2-4, 2020 June 4, 2:00 p.m. EDT – Chris Anzalone, Ph.D., Arrowhead’s president an...
After years of struggling to deliver on its promise, RNA interference (RNAi) finally appears poised for commercial success. The gene-silencing technique was developed decades ago to tune the expression of genes that drive or protect against disease, but a string of clinical failures left investo...
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
2024-06-05 05:00:08 ET Andrea Tan from Goldman Sachs issued a price target of $31.00 for ARWR on 2024-06-05 02:24:00. The adjusted price target was set to $31.00. At the time of the announcement, ARWR was trading at $25.29. The overall price target consensus is at $60.00...
On Monday, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) released topline results from the Phase 3 PALISADE study of plozasiran in patients with gen...
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday. Shares of Stericycle, Inc. (NASDAQ:SRCL) rose sharply during ...